|16.94||-0.4300||-2.48%||Vol 703.00K||1Y Perf -55.94%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||0.44 2.60%|
|Target Price||25.80||Analyst Rating||Strong Buy 1.43|
|Potential %||52.30||Finscreener Ranking||★★★★ 53.96|
|Insiders Trans % 3/6/12 mo.||-/-100/-100||Value Ranking||★★★ 50.83|
|Insiders Value % 3/6/12 mo.||-/-100/-100||Growth Ranking||★★★ 51.94|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||3.02||Earnings Rating||Buy|
|Market Cap||2.72B||Earnings Date||3rd Nov 2021|
Today's Price Range
5 Year PE Ratio Range
|10 Years||1 323.53%|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||3rd Nov 2021|
|Estimated EPS Next Report||-0.26|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||1.10M|
|Avg. Monthly Volume||1.29M|
|Avg. Quarterly Volume||1.57M|
ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) stock closed at 16.94 per share at the end of the most recent trading day (a -2.48% change compared to the prior day closing price) with a volume of 704.33K shares and market capitalization of 2.72B. Is a component of Russell 1000 indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 580 people. ACADIA Pharmaceuticals Inc. CEO is Stephen R. Davis.
The one-year performance of ACADIA Pharmaceuticals Inc. stock is -55.94%, while year-to-date (YTD) performance is -68.31%. ACAD stock has a five-year performance of -51.57%. Its 52-week range is between 15.68 and 57.46, which gives ACAD stock a 52-week price range ratio of 3.02%
ACADIA Pharmaceuticals Inc. currently has a PE ratio of -10.10, a price-to-book (PB) ratio of 4.75, a price-to-sale (PS) ratio of 5.79, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -34.30%, a ROC of -40.38% and a ROE of -41.40%. The company’s profit margin is -56.25%, its EBITDA margin is -56.10%, and its revenue ttm is $463.36 Million , which makes it $2.88 revenue per share.
Of the last four earnings reports from ACADIA Pharmaceuticals Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.26 for the next earnings report. ACADIA Pharmaceuticals Inc.’s next earnings report date is 03rd Nov 2021.
The consensus rating of Wall Street analysts for ACADIA Pharmaceuticals Inc. is Strong Buy (1.43), with a target price of $25.8, which is +52.30% compared to the current price. The earnings rating for ACADIA Pharmaceuticals Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
ACADIA Pharmaceuticals Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
ACADIA Pharmaceuticals Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 20.16, ATR14 : 0.65, CCI20 : 58.48, Chaikin Money Flow : 0.05, MACD : -0.39, Money Flow Index : 55.54, ROC : 2.48, RSI : 46.61, STOCH (14,3) : 68.48, STOCH RSI : 0.68, UO : 60.83, Williams %R : -31.52), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of ACADIA Pharmaceuticals Inc. in the last 12-months were: Austin D. Kim (Option Excercise at a value of $153 825), Austin D. Kim (Sold 12 589 shares of value $558 864 ), Elena Ridloff (Option Excercise at a value of $0), Elena Ridloff (Sold 4 099 shares of value $178 975 ), Michael J. Yang (Option Excercise at a value of $0), Michael J. Yang (Sold 2 367 shares of value $112 813 ), Srdjan Stankovic (Option Excercise at a value of $3 034 632), Srdjan Stankovic (Sold 110 461 shares of value $5 882 272 ), Stephen R. Davis (Option Excercise at a value of $0), Stephen R. Davis (Sold 28 489 shares of value $1 189 814 )
Thu, 23 Sep 2021 07:55 GMT ACADIA Pharmaceuticals (ACAD) Gets a Hold Rating from Needham- TipRanks. All rights reserved.
Thu, 05 Aug 2021 14:55 GMT ACADIA: DRP Treatments Path Ahead Unclear, yet Current Risk/Reward Appears Favorable- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.